AFT Pharmaceuticals expects to break even this year despite launch delays

Rebecca Howard
Thu, 02 Aug 2018

By Rebecca Howard Aug. 3 (BusinessDesk) - AFT Pharmaceuticals, which makes the Maxigesic painkiller, continues to target reaching breakeven by the end of this financial year regardless of whether it obtains any additional licensing income. In the last financial year to the end of March, its loss narrowed to $12.7 million from $18.4 million, Chair David Flacks told shareholders at the annual general meeting in Auckland today that Maxigesic is now licensed in 125 countries – up from 110 at the end of its 2017 financial year – and the c...

Try free for 10 days

Trustworthy, balanced journalism every day from our growing team of New Zealand business reporters and commentators, plus more in our weekend magazine section, The Life.

Instant News Alerts based on keywords you choose or journalists you follow
Our Daily Digest of all stories at 6am, midday or 6pm
A custom library of your saved stories
An industry-leading search engine
Try for 10 days without paying and if you’re not convinced cancel with just two clicks.

Support quality New Zealand journalism by subscribing today.

Find out more

Not convinced yet?

Subscribe to our Daily News Update free newsletter.

Policy

ELECTION 2020: Scared or excited about a Labour-Green govt?

Paul McBeth | Thu, 24 Sep 2020

Finance professionals have grown comfortable with Grant Robertson over the past three years. Will a new governing arrangement change that?

Law & Regulation

The FMA is running out of patience

Dan Brunskill | Thu, 24 Sep 2020

Financial services firms that keep failing compliance tests can expect to end up in court, says the FMA boss, Rob Everett.

Law & Regulation

Conduct complaint upheld against quake claims lawyer

Victoria Young | Thu, 24 Sep 2020

However, Grant Shand says it's a win.

Partner Content

The whole story behind good investment decisions

If there was ever a time when strong financial metrics were the single trademark of a good company, that time has long passed. Responsible investors need to know beyond the profit a company will generate this year or next.